Kistler-Tiffany Companies’s Aprea Therapeutics APRE Stock Holding History

Kistler-Tiffany Companies’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$79	Hold	25	–	–	﹤0.01%	887
2023 Q1	$111	Hold	25	–	–	﹤0.01%	782
2022 Q4	$166	Hold	25	–	–	﹤0.01%	789
2022 Q3	$0	Hold	25	–	–	﹤0.01%	780
2022 Q2	$0	Hold	25	–	–	﹤0.01%	761
2022 Q1	$1K	Hold	25	–	–	﹤0.01%	714
2021 Q4	$1K	Hold	25	–	–	﹤0.01%	690
2021 Q3	$3K	Hold	25	–	–	﹤0.01%	655
2021 Q2	$2K	Hold	25	–	–	﹤0.01%	655
2021 Q1	$3K	Hold	25	–	–	﹤0.01%	589
2020 Q4	$2K	Buy	+25	New	+$11.9K	﹤0.01%	586

Other funds holding APRE

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Kistler-Tiffany Companies's APRE Position: Q2 2023 in Review

Kistler-Tiffany Companies held its Aprea Therapeutics (APRE) position steady in Q2 2023 at 25 shares worth $79. The position accounts for ﹤0.01% of the portfolio, ranked #887.

Kistler-Tiffany Companies first reported a position in APRE in Q4 2020 and has held it in 11 quarters since. The position peaked at $3K in Q3 2021. 19 funds tracked by Wall St. Rank hold APRE as of Q2 2023.

Kistler-Tiffany Companies held 25 shares of Aprea Therapeutics worth $79 as of Q2 2023.
Kistler-Tiffany Companies left its Aprea Therapeutics share count unchanged in Q2 2023.
Aprea Therapeutics made up ﹤0.01% of Kistler-Tiffany Companies's portfolio in Q2 2023, its #887 holding.
Kistler-Tiffany Companies first reported a position in Aprea Therapeutics in Q4 2020 and has held it in 11 quarters since.
Kistler-Tiffany Companies's Aprea Therapeutics position peaked at $3K in Q3 2021.
19 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2023.

Based on Kistler-Tiffany Companies's 13F filing for Q2 2023, filed 1 Aug 2023.